Recommended PPIs for Children
For children ≥1 year with documented GERD, omeprazole (0.7-3.3 mg/kg/day), lansoprazole (0.7-3 mg/kg/day), or esomeprazole (0.7-3.3 mg/kg/day) are the FDA-approved first-line PPIs; for adolescents 12-17 years, rabeprazole 20 mg daily is also approved. 1
Age-Specific PPI Recommendations
Infants (<1 year)
- PPIs are NOT recommended for typical infant reflux or irritability 1
- Placebo-controlled trials show PPIs provide no benefit over placebo for reducing crying/fussiness in infants 1, 2
- PPIs may increase risk of lower respiratory tract infections, gastroenteritis, and necrotizing enterocolitis in this age group 1
- Exception: Consider only if documented erosive esophagitis on endoscopy, despite the limited FDA approval
Children 1-11 Years
FDA-approved options with dosing:
Omeprazole: 0.7-3.3 mg/kg/day (ages 2-16 years)
- Capsule contents can be sprinkled on soft foods
- Effective dosage range demonstrated in clinical trials 1
Lansoprazole: 0.7-3 mg/kg/day (ages 1-17 years)
Esomeprazole: 0.7-3.3 mg/kg/day (ages 1-17 years)
- Sprinkle capsule contents on soft foods or administer in juice via NG tube 1
Adolescents 12-17 Years
All above options PLUS:
- Rabeprazole: 20 mg daily (oral tablet) 1
- Studies show similar symptom improvement at 0.5 mg/kg and 1 mg/kg doses 2
Critical Prescribing Principles
When to Use PPIs
Appropriate indications:
- Documented erosive esophagitis on endoscopy
- Symptomatic GERD unresponsive to lifestyle modifications
- Esophagitis refractory to H2-receptor antagonists 1
- Eosinophilic esophagitis (considered standard of care) 3
Inappropriate indications (avoid):
- Uncomplicated infant regurgitation
- Nonspecific irritability in infants
- Without objective diagnostic confirmation in older children 1, 4
Formulation Selection by Age
- Ages 1-5 years: Prefer sprinkle formulations (omeprazole, lansoprazole, esomeprazole) mixed with soft foods
- Ages 6-11 years: Sprinkle formulations or disintegrating tablets (lansoprazole)
- Ages ≥12 years: Standard tablets acceptable; rabeprazole becomes an option 1
Safety Considerations and Monitoring
Known Adverse Effects
- Common (up to 14%): Headaches, diarrhea, constipation, nausea 1
- Serious concerns with prolonged use (>2.5 years):
Duration of Therapy
- Initial trial: 4-8 weeks for symptom assessment 1
- Maintenance: Use shortest effective duration
- Reassess regularly for deprescribing opportunities 4
- Long-term use (>11 years) documented in small numbers but requires careful risk-benefit analysis 1
Comparative Efficacy
PPIs vs H2-Receptor Antagonists:
- PPIs superior for symptom relief and healing erosive esophagitis 1
- H2RAs develop tachyphylaxis within 6 weeks, limiting long-term use 1
- Consider H2RAs (ranitidine 5-10 mg/kg/day divided 2-3 times daily) for short-term use or step-down therapy 1, 5
Between PPIs:
- No robust evidence favoring one PPI over another in children 2
- Choice based on FDA approval for age, available formulations, and dosing convenience
Common Pitfalls to Avoid
Overprescribing in infants: Most infant reflux is physiologic and self-limiting; PPIs provide no benefit and carry infection risks 1, 4
Prescribing without objective diagnosis: Use endoscopy or pH monitoring to confirm GERD before initiating PPIs in unclear cases 5
Indefinite continuation: Establish planned reassessment and step-down strategy at initiation 4
Ignoring weight-based dosing: Children require higher mg/kg doses than adults due to greater hepatic metabolic capacity 6
Wrong formulation for age: Ensure age-appropriate formulation for medication adherence 1
Not FDA-Approved for Pediatrics
- Pantoprazole: No pediatric indication (adult dose 40 mg daily only) 1
- Dexlansoprazole: No pediatric indication 1
These should be avoided unless all approved options have failed and specialist consultation obtained.